Myriad Genetics Inc - Company Profile
Powered by
All the data and insights you need on Myriad Genetics Inc in one report.
- Save hours of research time and resources with
our up-to-date Myriad Genetics Inc Strategy Report
- Understand Myriad Genetics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, engaged in the discovery and commercialization of molecular diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions, and corresponding proteins to assess a person’s risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient’s likelihood of responding to a particular drug. Myriad markets its products through sales force in Europe and Canada and distributor agreements in countries in Canada, Middle East, Asia, and Australia. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, Italy, Germany, Japan, Australia, and the Netherlands. Myriad is headquartered in Salt Lake City, Utah, the US.
Myriad Genetics Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
- | - |
BRAC Analysis | BRACAnalysis |
Colaris | BRACAnalysis CDx |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Asset Purchase | In February, the company acquired select assets including the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah, the US from Intermountain Precision Genomics. |
2024 | Contracts/Agreements | In February, the company partnered with the National Cancer Center Hospital East in Japan to investigate the prognostic and predictive significance of molecular residual disease testing. |
2024 | Contracts/Agreements | In January, the company signed an agreement to acquire certain assets from Intermountain Precision Genomics’ laboratory business. |
Competitor Comparison
Key Parameters | Myriad Genetics Inc | Quest Diagnostics Inc | Hologic Inc | Exact Sciences Corp | Natera Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Salt Lake City | Secaucus | Marlborough | Madison | Austin |
State/Province | Utah | New Jersey | Massachusetts | Wisconsin | Texas |
No. of Employees | 2,700 | 40,000 | 6,990 | 6,500 | 3,282 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
S. Louise Phanstiel | Chairman | Executive Board | - | 64 |
Paul J. Diaz | Chief Executive Officer; President; Director | Executive Board | 2020 | 61 |
Scott Leffler | Chief Financial Officer | Senior Management | 2024 | - |
Sam Raha | Chief Operating Officer | Senior Management | 2023 | - |
Kevin R. Haas, Ph.D. | Chief Technology Officer | Senior Management | - | 38 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer